A kind of alginate lyase mutant Pl7M and its application
P17M, a mutant of alginate lysase with significantly improved enzyme activity, was obtained through homologous modeling, site-directed saturation mutations and combined mutations, and efficient preparation was achieved with Bacillus subtilis as the host, solving the application of alginate lysase in the prior art The problem of limitation improves enzyme activity and thermal stability, reduces production costs, and lays the foundation for industrial application.
Patent Information
- Application Number
- CN202410088844.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-01-23
AI Technical Summary
The application of existing alginate lyases is limited by the problems of high cost and structural incompleteness, and there are problems of environmental pollution and many by-products in chemical processing.
Through homologous modeling, site-directed saturation mutations and combination mutations, the alginate lyase mutant P17M with significantly improved enzyme specific activity was obtained, and efficient preparation was achieved with Bacillus subtilis as the host.
It improves enzyme activity and thermal stability, reduces production costs, and lays the foundation for the industrial application of alginate lysase.
Smart Images

Figure CN117965508B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of molecular biology and protein engineering, and specifically relates to an alginate lyase mutant Pl7M and an application thereof. Background Art
[0002] Alginate mainly exists in the cell wall and intercellular matrix of brown algae. As a marine acidic polysaccharide, alginate is mainly composed of mannuronic acid and guluronic acid randomly polymerized through glycosidic bonds. Due to its large molecular weight, alginate has defects such as high viscosity and low bioavailability. As a degradation product of alginate, alginate oligosaccharides have good solubility, biological activity and bioavailability, so they have better application value in many fields. At present, the processing methods of alginate oligosaccharides mainly consist of chemical method and enzymatic method. The chemical method decomposes alginate by strong acid and alkali, which has the advantages of fast reaction speed and simple process, but the product structure is incomplete, there are many by-products and environmental pollution, which limit its wide application. Compared with the chemical method, the enzymatic method as a new technology is currently receiving more and more attention from the industry, which has the advantages of mild reaction conditions and intact product structure.
[0003] Therefore, in order to expand the application scope of alginate lyase, further research on alginate lyase has important practical significance. Summary of the invention
[0004] Based on this, the present invention provides an alginate lyase mutant Pl7M and its application, which effectively improves the enzyme activity and thermal stability, laying a solid foundation for the next step of industrial application.
[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0006] A alginate lyase mutant P17M, the amino acid sequence of the alginate lyase mutant P17M is shown in SEQ ID NO.1.
[0007] Preferably, the sequence encoding the amino acid is a polynucleotide sequence, and the polynucleotide sequence is shown as SEQ ID NO.2.
[0008] The present invention also provides a recombinant expression vector, which comprises the polynucleotide sequence of the alginate lyase mutant Pl7M.
[0009] The present invention also provides a recombinant engineering bacterium, wherein the recombinant engineering bacterium comprises the recombinant expression vector.
[0010] Preferably, the recombinant engineered bacteria uses an engineered strain of Bacillus subtilis as a host.
[0011] Preferably, the Bacillus subtilis includes Bacillus subtilis WB800N.
[0012] The present invention also provides an application of the recombinant engineered bacteria in preparing a high enzyme specific activity mutant P17M.
[0013] In the previous study, alginate lyase Pl7AaM was obtained through rational protein design (patent application number CN202211412004.1). After the alginate lyase Pl7AaM was treated in a water bath at 40°C and 45°C for 1 hour, the residual enzyme activity was 95.2% and 42.6%, respectively, which was higher than that of various alginate lyases reported. In the further research process, we found that the cost of using alginate lyase Pl7AaM was high, which limited its industrial application. This patent uses alginate lyase Pl7AaM as a starting template, and obtains alginate lyase mutant Pl7M with improved enzyme specific activity through site-directed saturation mutation and combined mutation. In addition, Bacillus subtilis was used as a host to achieve efficient preparation of mutant Pl7M, laying the foundation for its industrial application.
[0014] The present invention is mainly achieved through the following technologies: (1) obtaining the three-dimensional structure of alginate lyase Pl7AaM by homology modeling, and obtaining the key amino acid sites of alginate lyase Pl7AaM binding to substrate and hydrolysis by molecular docking; (2) obtaining effective mutants S58R, Q134F and Q246W by site-directed saturation mutagenesis; (3) obtaining the best mutant Pl7M by combining effective mutants for mutation, and its enzyme specific activity is 1.53 times that of the starting template alginate lyase Pl7AaM; (4) using Bacillus subtilis as a host to achieve efficient preparation of mutant Pl7M.
[0015] Compared with the prior art, the technical advantages of the present invention are as follows: the present invention obtains an alginate lyase mutant Pl7M with significantly improved enzyme specific activity through site-directed inclusion mutation and combined mutation, and realizes efficient expression of the mutant Pl7M using Bacillus subtilis as a host, laying a foundation for the industrial application of the mutant Pl7M. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The three-dimensional conformation and molecular docking diagram of alginate lyase Pl7AaM;
[0017] Figure 2 The optimal reaction temperature and thermal stability results of alginate lyase P17AaM and mutant P17M are shown in FIG.
[0018] Figure 3 The optimal reaction pH and pH stability results of alginate lyase P17AaM and mutant P17M are shown in FIG.
[0019] Figure 4It is the result diagram of substrate specificity of alginate lyase P17AaM and mutant P17M;
[0020] Figure 5 Flowchart for the construction of the Bacillus subtilis expression vector for mutant P17M;
[0021] Figure 6 This is a diagram of the high-density fermentation results of recombinant Bacillus subtilis P35. DETAILED DESCRIPTION
[0022] The present invention is further described in detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. The molecular biology experimental methods not specifically described in the following examples are all carried out with reference to the specific methods listed in the book Molecular Cloning Laboratory Manual (3rd Edition) by J. Sambrook, or according to the kits and product instructions; the reagents and biological materials, unless otherwise specified, can be obtained from commercial sources.
[0023] The experimental materials and reagents involved in the present invention are as follows:
[0024] 1. Strains and vectors: Escherichia coli strain Top10 (Cat. No. T0008) and Bacillus subtilis WB800N (Cat. No. T0105) were purchased from Wuhan Miaoling Biotechnology Co., Ltd. The expression vector pPICZαA-pl7aam was constructed by previous experiments (patent application number CN202211412004.1). cry -SP bs2 -aprbpm was constructed by previous experiments (patent application number: CN202210419863.7, i.e., pHY- Pcry-SPBs2-aprbpm).
[0025] 2. Enzymes and kits: Q5 high-fidelity Taq enzyme MIX was purchased from NEB; plasmid extraction (#DP103-03) and gel purification kit (#DP209-02) were purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.; high-fidelity enzyme PrimeSTAR® HS (Premix) and restriction endonucleases were purchased from Bio-Rad Biotechnology (Beijing) Co., Ltd.
[0026] 3. Culture medium: E. coli culture medium is LB liquid culture medium (1% (w / v) peptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl, pH 7.0). LBK is LB liquid culture medium with 30μg / mL kanamycin. LBA is LB liquid culture medium with ampicillin added, the concentration is 25μg / mL. LBT is LB liquid culture medium with tetracycline added, the concentration is 50μg / mL. For LB, LBK and LBA solid culture medium (i.e. LB plate, LBK plate and LBA plate), add 2.5% agar.
[0027] The composition of maltose medium is as follows: 2.5% yeast extract, 1.5% peptone, 4% maltose, 1% sodium citrate, 0.3% calcium chloride, 1% dipotassium hydrogen phosphate, and the balance water.
[0028] The high-density fermentation medium has the following components: maltose 7%, soybean meal 2.5%, yeast powder 1.5%, bran 2%, dipotassium hydrogen phosphate 1%, trisodium citrate 0.3%, calcium chloride 0.3%, and the balance water.
[0029] 4. Reagents used for the determination of alginate lyase activity: The DNS method was used to determine the activity of alginate lyase. The main reagents included the substrate sodium alginate (concentration of 0.5%, m / v) and the color developer DNS reagent ((6.3‰ (w / v) 3,5-dinitrosalicylic acid; 18.2% (w / v) potassium sodium tartrate tetrahydrate; 5‰ (w / v) phenol; 5‰ (w / v) anhydrous sodium sulfite)).
[0030] Example 1 Three-dimensional modeling, homology modeling and molecular docking of alginate lyase P17AaM
[0031] The three-dimensional modeling process of alginate lyase Pl7AaM is as follows: (1) First, the homologous templates of alginate lyase Pl7AaM are matched by the online software SWISS-MODEL (see URL: https: / / swissmodel.expasy.org / ); (2) Homology modeling is performed based on the homologous template with the highest similarity to obtain the three-dimensional conformation of alginate lyase Pl7AaM (such as Figure 1 A in the figure).
[0032] The molecular docking software Autodock viner was used to obtain the conformational diagram of alginate lyase Pl7AaM binding to the substrate (such as Figure 1B in the figure). The three-dimensional conformation obtained by analyzing the software Pymol revealed that the key amino acid sites for the binding of alginate lyase Pl7AaM to the substrate include serine at position 58 (S58), asparagine at position 60 (N60), threonine at position 81 (T81), glutamine at position 134 (Q134), serine at position 139 (S139) and glutamine at position 246 (Q246). By performing saturation mutations on the above six amino acid sites, mutants with improved enzyme specific activity were obtained.
[0033] Example 2 Construction of E. coli expression vector pET28a-pl7Aam
[0034] Since E. coli has the advantages of simple operation, short experimental cycle, and easy purification of recombinant expressed proteins, this patent uses E. coli BL21 (DE3) as the host for site-directed saturation mutagenesis experiments. Before conducting site-directed saturation mutagenesis experiments, it is necessary to construct the E. coli expression vector pET28a-pl7Aam.
[0035] The construction process of E. coli expression vector pET28a-pl7aam is as follows:
[0036] (1) Using the vector pPICZαA-pl7aam as a template, PCR amplification was performed using primers pl7aam-BamHI-fw (CGCGGATCCTTAGATTTTTATCGCTG) and primers pl7aam-XhoI-rev (GTGCTCGAGG TCGTGAGTAGCATCTAG). The PCR reaction system is shown in Table 1, and the PCR reaction conditions are as follows: pre-denaturation at 94°C for 5 min; denaturation at 94°C for 10 s, annealing at 50°C for 20 s, and extension at 72°C for 90 s, for 33 cycles; the PCR amplification effect was detected by agarose electrophoresis.
[0037] Table 1 Gene amplification reaction system
[0038]
[0039] (2) The PCR product obtained by amplification was purified and recovered. The purification process was carried out according to the gel purification kit (#DP209-02). The purified PCR product was digested with restriction endonucleases BamHI and XhoI. The reaction system was shown in Table 2. After the digestion reaction was carried out at 37°C for 6 hours, the product was purified according to the DNA product purification kit (#DP204).
[0040] Table 2 Enzyme digestion reaction system
[0041]
[0042] (3) The E. coli vector pET28a was digested with restriction endonucleases BamHI and XhoI. The digestion reaction system was shown in Table 2 (the PCR product was replaced with the vector pET28a). After the digestion reaction was carried out at 37°C for 6 h, the product was purified according to the DNA product purification kit (#DP204). The purified PCR product and the vector pET28a were ligated. The ligation reaction system was shown in Table 3. The reaction was carried out at 4°C for 16 h.
[0043] Table 3 Ligation reaction system
[0044]
[0045] (4) The product after the ligation reaction was transferred into Escherichia coli Top10. The transformation process was as follows: (1) After placing the Escherichia coli competent cells Top10 (Tiangen Biochemical Technology (Beijing) Co., Ltd.) on ice for 30 minutes, the ligation product obtained in step (3) was aspirated with a 20 μL pipette and transferred to a centrifuge tube containing 100 μL of Escherichia coli competent cells; (2) The Escherichia coli competent cells Top10 containing the ligation product were heat-shocked at 42°C for 90 seconds and then placed on ice for 5 minutes; (3) The heat-shocked Escherichia coli competent cells Top10 were inoculated into 500 μL of LB liquid culture medium and cultured at 37°C, 200 rpm, for 1 hour. The cultured bacterial solution was evenly spread on LBK plate, placed in a 37℃ incubator, cultured for 18h; (4) The E. coli transformants obtained by 37℃ culture were inoculated into LBK liquid culture medium in the form of single colonies, cultured at 37℃, 200rpm, and then cultured for 1h before performing bacterial liquid PCR; (5) Using the cultured bacterial liquid as a template, PCR amplification experiment was performed using primers pl7aam-BamHI-fw and pl7aam-XhoI-rev. The PCR reaction system is shown in Table 4, and the reaction conditions are: 94℃ pre-denaturation for 5min; 94℃ denaturation for 10s, 50℃ annealing for 30s, 72℃ extension for 90s, and 33 cycles; (6) The PCR amplification product was analyzed by agarose electrophoresis. The size of the amplified product was about 800 bp, indicating that it was the target recombinant transformant. The recombinant transformant verified by bacterial liquid PCR was sent to Guangzhou Aiji Biotechnology Co., Ltd. for sequencing. According to the sequencing results, the E. coli expression vector pET28a-pl7aam was finally obtained.
[0046] Table 4 Bacterial liquid PCR reaction system
[0047]
[0048] Example 3 Site-directed saturation mutagenesis
[0049] According to the analysis results of Example 1, six amino acid sites, S58, N60, T81, Q134, S139 and Q246, were selected for saturation mutation. The main contents of the experiment are as follows: (1) designing site-directed saturation mutagenesis primers; (2) constructing a mutant library; (3) screening the mutant library; (4) determining effective mutants by sequencing.
[0050] Primers were designed to construct saturation mutant expression vectors corresponding to each site. The specific sequences of the primers are shown in Table 5 below.
[0051] Table 5 Site-directed saturation mutant primers
[0052]
[0053] The mutant library construction process is as follows (taking the S58 site as an example, and the others are similar): (1) Using the vector pET28a-pl7aam as a template, PCR amplification is performed using the upstream and downstream primers S58-fw and S58-rev. The PCR amplification system is shown in Table 1, and the PCR amplification conditions are: 98°C pre-denaturation for 5 min; 98°C denaturation for 10 s, 54°C annealing for 30 s, 72°C extension for 30 s, and 33 cycles; (2) Agarose electrophoresis is used to detect the PCR amplification results, and the correctly amplified PCR products are purified and recovered. The specific experimental process refers to Example 2; (3) 1 μL of restriction endonuclease DpnI (Cat. No. 1235S, Bio-Rad Biotechnology (Beijing) Co., Ltd.) is added to the purified PCR product and reacted at 37°C for 3 h; (4) The PCR product after DpnI digestion is transformed into Escherichia coli competent cells BL21 (DE3), and the transformation process is consistent with Example 2.
[0054] The mutant library screening process is as follows: (1) The obtained transformants are inoculated into a 24-well plate containing 2 ml LBK liquid culture medium in each well, cultured at 37°C for 4 hours, and then IPTG (final concentration is 1 mM) is added; (2) After the addition of IPTG, the fermentation conditions of the 24-well plate are changed to 16°C, 200 rpm. After induction culture for 4 hours under this condition, the culture is refrigerated and centrifuged at 6°C, 8000 rpm for 10 minutes, and the bacteria are collected; (3) The collected bacteria are ultrasonically disrupted and the supernatant is collected by centrifugation; (4) The alginate lyase activity of the supernatant is determined and analyzed; (5) The bacteria with enzyme activity higher than that of the control group are sent to Guangzhou Aiji Biotechnology Co., Ltd. for sequencing and classification, thereby obtaining effective mutants.
[0055] Through analysis and determination, it was finally found that the enzyme activity of the recombinant engineering bacteria corresponding to mutants S58R, Q134F and Q246W was greater than that of the control group. In order to accurately analyze these three mutants, they were first separated and purified. The separation and purification process is as follows: (1) Collect the recombinant engineering bacteria corresponding to mutants S58R, Q134F and Q246W, perform ultrasonic disruption, and collect the supernatant by centrifugation; (2) Use a 10 kDa ultrafiltration tube to ultrafilter and concentrate the supernatant enzyme solution; (3) Purify using a Ni-IDA protein purification kit.
[0056] The enzyme specific activities and kinetic parameters of the purified mutants S58R, Q134F and Q246W were measured respectively. The starting template P17AaM was used as the control during the whole experiment. The experimental results are shown in Table 6. The enzyme specific activities of the mutants S58R, Q134F and Q246W were 461.3 U / mg, 478.2 U / mg and 485.9 U / mg, respectively, which were 1.07 times, 1.11 times and 1.13 times of the starting template P17AaM, respectively. In addition, it can be seen from the table that the Michaelis constants K m All of them were lower than the starting template P17AaM, indicating that mutants S58R, Q134F and Q246W had better substrate affinity, which was more conducive to the enzyme catalytic reaction. Consistent with the enzyme specific activity, the maximum reaction rates of mutants S58R, Q134F and Q246W were all higher than the starting template P17AaM, indicating that mutants S58R, Q134F and Q246W had higher hydrolysis efficiency.
[0057] Table 6 Kinetic parameters of P17AaM and different mutant enzymes
[0058]
[0059] Example 4 Combination Mutation
[0060] The effective mutations S58R, Q134F and Q246W obtained in Example 3 were combined for mutation to further improve the enzyme specific activity of the starting template P17AaM. Since the mutant Q246W had the best effect, it was used as a template to construct the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F, respectively.
[0061] The construction process of expression vectors corresponding to different combination mutants was consistent with the construction process of saturation mutants in Implementation 3, except that the amplification primers were replaced with S58R-fw (GATGGTTAT AAAACGCGCACCAACACGAGTT), S58R-rev (AACTCGTGTTGGTGCGCG TT TTATAACCATC), Q134F-fw (CGCGTCATTATTGGTTTTATTCATGCTTCTAGC), Q134F-rev (GCTAGAAGCATGAATAAAACCAATAATGACGCG), Q246W-fw (CCGGTGTGTCCAAGTGGAACAAAACTGGTGATG) and Q246W-rev (CATCACC AGTTTTGTTCCACTTGGACACACCGG).
[0062] Through experiments, the expression vectors pET28a-pl7aam-246-58 (corresponding to mutant Q246W-S58R), pET28a-pl7aam-246-134 (corresponding to mutant Q246W-Q134F) and pET28a-pl7aam-246-58-134 (corresponding to mutant Q246W-Q134F) corresponding to the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F were finally obtained.
[0063] The construction, screening and purification of the recombinant engineering bacteria corresponding to the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F were all carried out with reference to Example 3. The purified combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F were finally obtained through the experiment. The enzyme specific activities and kinetic parameters of the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F were measured respectively. The starting template P17AaM was used as the control throughout the experimental process. The experimental results are shown in Table 7. As shown in Table 7, the combined mutations have a synergistic effect and can further improve the enzyme specific activity. The enzyme specific activities of the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F are 586.9 U / mg, 612.3 U / mg and 658.9 U / mg, respectively, which are 1.36 times, 1.42 times and 1.53 times of the starting template P17AaM, respectively. In addition, the affinity of the combined mutants Q246W-S58R, Q246W-Q134F and Q246W-S58R-Q134F for the substrate is also improved, and the corresponding Michaelis constants are all lower than the starting template P17AaM. Consistent with the enzyme specific activity, the maximum reaction rate of the combined mutants is higher than the starting template P17AaM. Since the combined mutant Q246W-S58R-Q134F has the best effect, it is used as a template for the next step of research. For ease of writing, the combined mutant Q246W-S58R-Q134F was named P17M, and its corresponding expression vector was named pET28a-P17M.
[0064] Table 7 Enzyme kinetic parameters of P17AaM and different combination mutants
[0065]
[0066] Example 7 Temperature characteristics of the recombinant mutant P17M
[0067] The enzyme activity of mutant Pl7M at different temperatures of 30-55°C was measured under pH 7.0 conditions. The enzyme activity at the highest temperature was determined as 100%, and the relative enzyme activity at other temperatures was calculated. The starting template Pl7AaM was used as a control throughout the experiment.
[0068] Depend on Figure 2 From A in the figure, we can know that the optimal reaction temperature of mutant Pl7M and starting template Pl7AaM is 45℃;
[0069] Compared with the starting template Pl7AaM, the mutant Pl7M has better activity in the range of 30℃ to 40℃, and the relative enzyme activity is higher than that of the starting template Pl7AaM.
[0070] Under pH 7.0 conditions, the residual enzyme activities of mutant Pl7M and starting template Pl7AaM were measured after treatment in a water bath at different temperatures (30℃ to 50℃) for 30 minutes, and the samples without heat treatment were used as controls.
[0071] Depend on Figure 2 From B, we can see that: in the range of 30℃ to 40℃, both the mutant Pl7M and the starting template Pl7AaM have good thermal stability. After 30 minutes of water bath treatment, the remaining enzyme activity is greater than 90%; when the heat treatment temperature is increased to 45℃, the remaining enzyme activity of the mutant Pl7M and the starting template Pl7AaM drops sharply to 40.1% and 42.5%, respectively; when the treatment temperature continues to increase to 50℃, the remaining enzyme activity of the mutant Pl7M and the starting template Pl7AaM is 10.6% and 13.2%, respectively.
[0072] Example 8 pH characteristics of the recombinant mutant P17M
[0073] The enzyme activities of mutant Pl7M and starting template Pl7AaM at pH 4.0-9.0 were measured at 45°C, and the enzyme activity at the highest pH was taken as 100%, and the relative enzyme activities at other pH values were calculated.
[0074] Depend on Figure 3 As shown in A, the optimal reaction pH of mutant P17M is 7.0, while the optimal reaction pH of starting template P17AaM is 8.0; in addition, mutant P17M has better activity in the range of pH 4.0 to 7.0.
[0075] At 25°C, the mutant Pl7M and the starting template Pl7AaM were placed at pH 4.0 to 9.0 for 4 hours and then the residual enzyme activity was measured, with the untreated sample as the control.
[0076] Depend on Figure 3 As shown in B, in the pH range of 5.0 to 8.0, both the mutant P17M and the starting template P17AaM have good stability, and the residual enzyme activity is greater than 80%.
[0077] Example 9 Substrate specificity of recombinant mutant P17M
[0078] Using sodium alginate (abbreviated as MG), sodium polymannuronate (abbreviated as M) and sodium polyguluronate (abbreviated as G) as substrates, the enzyme activities of mutant Pl7M and starting template Pl7AaM at pH 7.0 and 45°C were measured respectively. The substrate with the highest enzyme activity was set as 100%, and the relative activities of other substrates were calculated.
[0079] Depend on Figure 4It can be seen that the optimal reaction substrates for mutant P17M and starting template P17AaM are both sodium polymannuronate (abbreviated as M), followed by sodium alginate (abbreviated as MG) and sodium polyguluronate (abbreviated as G). Figure 4 It can be seen that the hydrolysis activity of mutant Pl7M on sodium alginate (abbreviated as MG) and sodium polyguluronate (abbreviated as G) is higher than that of the starting template Pl7AaM.
[0080] Example 10 Highly efficient preparation of recombinant mutant P17M
[0081] The efficient preparation of the recombinant mutant P17M can effectively reduce its production cost and lay the foundation for its large-scale application. So far, the heterologous expression host of alginate lyase is mainly Escherichia coli. Compared with Escherichia coli, Bacillus subtilis has many advantages such as: food-grade expression host, extracellular secretion expression, and easy high-density fermentation. This patent uses the food-grade expression host Bacillus subtilis WB800N to achieve efficient preparation of the recombinant mutant P17M, laying the foundation for its application in different industrial fields.
[0082] The vector pHY-P obtained by our research team through promoter optimization and signal peptide optimization cry -SP bs2 -aprbpm, the vector contains the efficient promoter Pcry and signal peptide SPbs2 (patent application number: CN202210419863.7). In this patent, the expression vector pHY-P cry -SP bs2 -aprbpm was used as a template, and the gene encoding gene P17M of the mutant P17M was substituted for the gene aprbpm carried by the vector itself by gene replacement, thereby obtaining the expression vector pHY-P cry -SP bs2 -Pl7M.
[0083] Expression vector pHY-P cry -SP bs2 -Pl7M construction process as follows Figure 5 As shown, the experimental process is as follows: (1) Using the expression vector pET28a-Pl7M obtained in Example 4 as a template, PCR amplification was performed using primers Pl7M-fw (5'-GCAACATGTCTGCGCAGGCTTTAGATTTTTATCGCTG-3') and Pl7M-rev (5'-ACAGC GTTATTATTATTGTTAGTCGTGAGTAGCAT-3'). The PCR amplification conditions and amplification system were all carried out in accordance with Example 2, and the gene Pl7M was obtained by amplification; (2) Using the vector pHY-P cry -SP bs2-aprbpm was used as a template, and PCR amplification was performed using primers pHY-fw (5'-CAATAATAATAACG CTGTG TG-3') and pHY-rev (5'-AGCCTGCGCAGACATGTTGCT-3'). The PCR amplification conditions and amplification system were all carried out according to Example 2. The framework pHY-P was obtained by amplification. cry -SP bs2 (the gene aprbpm was removed); (3) the framework pHY-P cry -SP bs2 The fusion system is shown in Table 8. The fusion PCR reaction conditions are: 98°C pre-denaturation for 20 s; 98°C denaturation for 10 s, 60°C annealing for 20 s, 72°C extension for 30 s, and 18 cycles; (4) The fusion product was transferred into E. coli competent cells Top10. The transformation and screening process were the same as in Example 2, except that the culture medium was replaced with LBA culture medium; (5) The plasmids of positive transformants were extracted and screened using a plasmid extraction kit (#DP103-03). The target plasmid was sent to Guangzhou Aiki Biotechnology Co., Ltd. for sequencing. According to the sequencing results, the expression vector pHY-P was finally obtained. cry -SP bs2 -Pl7M.
[0084] Table 8 Gene amplification reaction system
[0085]
[0086] The constructed expression vector pHY-P cry -SP bs2-pl7m was transferred into Bacillus subtilis WB800N. The experimental process was as follows: (1) a single colony (2-3 mm in diameter) was picked from the LB plate cultured at 37°C for 20 h, transferred to a 50 mL centrifuge tube containing 5 mL LB liquid culture medium, and shaken vigorously at 37°C overnight; (2) the culture that was shaken overnight was inoculated into 50 mL GM culture medium (LB + 0.5 M sorbitol) at a 1% inoculum, the OD in the shaking tube was measured, and the inoculation amount was controlled so that the OD of the culture medium after inoculation was between 0.19 and 0.2. 37℃, 200rpm, culture until OD600 = 0.8-1.0 (about 3-4 hours); (3) Take all the bacterial solution and put it in an ice water bath for 10 minutes, then centrifuge it at 4℃, 5000rpm for 8 minutes to collect the bacteria; (4) Wash the bacteria with 30mL pre-cooled electroporation buffer ETM (0.5M sorbitol, 0.5M mannitol and 10% glycerol), centrifuge it at 4℃, 5000rpm for 8 minutes, then remove the supernatant, and rinse it three times; (5) Resuspend the washed bacteria in 500μL ETM and dispense 100μL into each tube; (6) Add 1-6μL expression vector pHY-P to 100μL competent cells. cry -SP bs2 -Pl7M, incubate in ice bath for 5 min, add to pre-cooled electroporation cup (1mm), and electroporate once. Electroporation instrument settings: 1.5kv, 25μF, 200Ω, 1mm, electroporation once. (Duration between 4.5ms-5ms); (7) After the electroporation, immediately add 0.5mL recovery medium RM (LB+0.5M sorbitol+0.38M mannitol), 37℃, 120rpm, after 3h of recovery, spread the transformant on LBT solid plate and culture at 37℃ overnight.
[0087] The screening experiment was carried out with the recombinant transformants of Bacillus subtilis grown overnight on LBT solid plates as the experimental objects. The target Bacillus subtilis spores were picked one by one with a toothpick into a 24-well plate containing 1.6 mL of maltose medium in each well. After culturing at 37°C and 200 rpm for 24 hours, the supernatant was centrifuged and the enzyme activity was determined. Three enzyme-active dominant bacteria were obtained through the screening experiment, named P12, P35 and P65.
[0088] The recombinant engineered bacteria P12, P35 and P65 were further verified by shaking flask culture. Shake flask culture was carried out in a 250mL Erlenmeyer flask. First, the corresponding recombinant engineered bacteria were inoculated into a 50mL centrifuge tube containing 5mL maltose medium, and cultured at 30℃ and 220rpm for about 24h. The cultured recombinant subtilis spore engineered bacteria were inoculated into a 250mL Erlenmeyer flask containing 50mL maltose medium at a 1% (v / v) inoculation rate. The shaking flask culture conditions were 30℃ and 200rpm, and samples were taken for activity determination after 48h of culture. The enzyme activities of the recombinant engineered bacteria P12, P35 and P65 were 52.3U / mL, 61.6U / mL and 58.7U / mL respectively after 48 hours of shaking flask culture.
[0089] Since the recombinant engineered bacteria P35 has the highest activity under shake flask culture conditions, it is used as the target strain for high-density fermentation culture. The high-density fermentation of the recombinant engineered bacteria P35 was carried out in a 7L fermenter. The specific process is as follows: a single colony was inoculated into a 250mL triangular flask containing 50mL maltose medium, and cultured overnight at 30°C and 200rpm. Then, the recombinant engineered bacteria P35 cultured overnight was inoculated at a 1% (v / v) inoculation rate into a 500mL triangular flask containing 100mL maltose medium, and cultured overnight at 30°C and 200rpm. The recombinant engineered bacteria P35 cultured overnight for the second time was inoculated at a 10% (v / v) inoculation rate into a 7L fermenter containing 3L maltose medium. During the culture process, maltose medium was added in a timely manner according to the dissolved oxygen (not less than 10%).
[0090] The fermentation curve of recombinant engineering bacteria P35 is as follows Figure 6 As shown in A, after 60 h of culture, the fermentation enzyme activity reached a maximum of 725.6 U / mL.
[0091] In order to further improve the high-density fermentation enzyme activity of the recombinant engineered bacteria P35, the culture conditions in the 7L fermenter were optimized. First, the fermentation temperature was optimized and set to 30°C, 33°C, 36°C and 39°C, respectively. The pH was controlled at 6.0 and the stirring speed was 500rpm. Figure 6 From B, we can see that when the fermentation temperature is 36°C, the best fermentation enzyme activity reaches 978.7U / mL.
[0092] The culture pH was optimized based on the optimal culture temperature. During the culture process, the fermentation temperature was 36°C, the stirring speed was 400 rpm, and the pH was set to 5, 6, 7, and 8, respectively. Figure 6 It can be seen from C that when the fermentation pH is 7.0, the effect is best and the fermentation enzyme activity reaches 1175.9U / mL.
[0093] Based on the optimal culture temperature and pH, the reducing sugar concentration of the culture medium was optimized. During the culture process, the fermentation temperature was 36°C, the fermentation pH was 7.0, and the stirring speed was 400 rpm. The reducing sugar content was controlled at 0.5%, 1%, 1.5%, and 2%, respectively. Figure 6 From D in the figure, we can see that when the reducing sugar content is 1.5%, the effect is best and the fermentation enzyme activity reaches 1421.3U / mL.
[0094] Finally, it should be noted that the above embodiments are only illustrative of the principles, performance and efficacy of the present invention, and are not intended to limit the present invention. Anyone familiar with the technology may modify or change the above embodiments without violating the spirit and scope of the present invention. Therefore, all equivalent modifications or changes made by those with ordinary knowledge in the technical field without departing from the spirit and technical ideas disclosed by the present invention should still be covered by the claims of the present invention.
Claims
1. An alginate lyase mutant P17M, characterized in that: The amino acid sequence of the alginate lyase mutant P17M is shown in SEQ ID NO.
1.
2. A polynucleotide encoding an alginate lyase mutant P17M, characterized in that: The polynucleotide sequence is shown as SEQ ID NO.
2.
3. A recombinant expression vector, characterized in that: Comprising the polynucleotide encoding the alginate lyase mutant P17M as claimed in claim 2.
4. A recombinant engineered bacterium, characterized in that: Comprising the recombinant expression vector according to claim 3.
5. The recombinant engineered bacterium according to claim 4, characterized in that The engineered strain of Bacillus subtilis was used as the host.
6. The recombinant engineered bacterium according to claim 5, characterized in that The Bacillus subtilis is Bacillus subtilis WB800N.
7. Use of the recombinant engineered bacterium according to any one of claims 4 to 6 in preparing a mutant P17M with high enzyme specific activity.
